Cytokinetics Announces Encouraging Results From Two Phase II Clinical Trials Evaluating CK-2017357 in Patients With Amyotrophic Lateral Sclerosis

Cytokinetics, Incorporated CYTK announced today encouraging results from two Phase II clinical trials evaluating CK-2017357 in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease. In these studies, CK-2017357 was determined to be safe and well-tolerated when dosed with riluzole, the only approved treatment for ALS. The clinical trials results were reported in an oral presentation and a poster at the American Academy of Neurology 64th Annual Meeting in New Orleans, Louisiana.